Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities
Different from surgery, chemical therapy, radio-therapy and target therapy, Chimeric antigen receptor-modified T (CAR-T) cells, a novel adoptive immunotherapy strategy, have been used successfully against both hematological tumors and solid tumors. Although several problems have reduced engineered C...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.871661/full |
| _version_ | 1811292177527996416 |
|---|---|
| author | Long Chen Fukun Chen Huatao Niu Jindan Li Yongzhu Pu Conghui Yang Yue Wang Rong Huang Ke Li Yujie Lei Yunchao Huang |
| author_facet | Long Chen Fukun Chen Huatao Niu Jindan Li Yongzhu Pu Conghui Yang Yue Wang Rong Huang Ke Li Yujie Lei Yunchao Huang |
| author_sort | Long Chen |
| collection | DOAJ |
| description | Different from surgery, chemical therapy, radio-therapy and target therapy, Chimeric antigen receptor-modified T (CAR-T) cells, a novel adoptive immunotherapy strategy, have been used successfully against both hematological tumors and solid tumors. Although several problems have reduced engineered CAR-T cell therapeutic outcomes in clinical trials for the treatment of thoracic malignancies, including the lack of specific antigens, an immunosuppressive tumor microenvironment, a low level of CAR-T cell infiltration into tumor tissues, off-target toxicity, and other safety issues, CAR-T cell treatment is still full of bright future. In this review, we outline the basic structure and characteristics of CAR-T cells among different period, summarize the common tumor-associated antigens in clinical trials of CAR-T cell therapy for thoracic malignancies, and point out the current challenges and new strategies, aiming to provide new ideas and approaches for preclinical experiments and clinical trials of CAR-T cell therapy for thoracic malignancies. |
| first_indexed | 2024-04-13T04:41:33Z |
| format | Article |
| id | doaj.art-72f8f3547dc14a79b5ed936f3fe290f6 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-13T04:41:33Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-72f8f3547dc14a79b5ed936f3fe290f62022-12-22T03:01:59ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-07-011310.3389/fimmu.2022.871661871661Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and OpportunitiesLong Chen0Fukun Chen1Huatao Niu2Jindan Li3Yongzhu Pu4Conghui Yang5Yue Wang6Rong Huang7Ke Li8Yujie Lei9Yunchao Huang10Department of PET/CT Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, ChinaDepartment of Nuclear Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, ChinaDepartment of Neurosurgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, ChinaDepartment of PET/CT Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, ChinaDepartment of PET/CT Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, ChinaDepartment of PET/CT Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, ChinaDepartment of PET/CT Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, ChinaDepartment of PET/CT Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, ChinaDepartment of Cancer Biotherapy Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, ChinaDepartment of Thoracic Surgery I, Key Laboratory of Lung Cancer of Yunnan Province, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, ChinaDepartment of Thoracic Surgery I, Key Laboratory of Lung Cancer of Yunnan Province, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, ChinaDifferent from surgery, chemical therapy, radio-therapy and target therapy, Chimeric antigen receptor-modified T (CAR-T) cells, a novel adoptive immunotherapy strategy, have been used successfully against both hematological tumors and solid tumors. Although several problems have reduced engineered CAR-T cell therapeutic outcomes in clinical trials for the treatment of thoracic malignancies, including the lack of specific antigens, an immunosuppressive tumor microenvironment, a low level of CAR-T cell infiltration into tumor tissues, off-target toxicity, and other safety issues, CAR-T cell treatment is still full of bright future. In this review, we outline the basic structure and characteristics of CAR-T cells among different period, summarize the common tumor-associated antigens in clinical trials of CAR-T cell therapy for thoracic malignancies, and point out the current challenges and new strategies, aiming to provide new ideas and approaches for preclinical experiments and clinical trials of CAR-T cell therapy for thoracic malignancies.https://www.frontiersin.org/articles/10.3389/fimmu.2022.871661/fullthoracic malignancieschimeric antigen receptor-modified T cellsimmunotherapytargeting specific antigenssolid tumor |
| spellingShingle | Long Chen Fukun Chen Huatao Niu Jindan Li Yongzhu Pu Conghui Yang Yue Wang Rong Huang Ke Li Yujie Lei Yunchao Huang Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities Frontiers in Immunology thoracic malignancies chimeric antigen receptor-modified T cells immunotherapy targeting specific antigens solid tumor |
| title | Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities |
| title_full | Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities |
| title_fullStr | Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities |
| title_full_unstemmed | Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities |
| title_short | Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities |
| title_sort | chimeric antigen receptor car t cell immunotherapy against thoracic malignancies challenges and opportunities |
| topic | thoracic malignancies chimeric antigen receptor-modified T cells immunotherapy targeting specific antigens solid tumor |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.871661/full |
| work_keys_str_mv | AT longchen chimericantigenreceptorcartcellimmunotherapyagainstthoracicmalignancieschallengesandopportunities AT fukunchen chimericantigenreceptorcartcellimmunotherapyagainstthoracicmalignancieschallengesandopportunities AT huataoniu chimericantigenreceptorcartcellimmunotherapyagainstthoracicmalignancieschallengesandopportunities AT jindanli chimericantigenreceptorcartcellimmunotherapyagainstthoracicmalignancieschallengesandopportunities AT yongzhupu chimericantigenreceptorcartcellimmunotherapyagainstthoracicmalignancieschallengesandopportunities AT conghuiyang chimericantigenreceptorcartcellimmunotherapyagainstthoracicmalignancieschallengesandopportunities AT yuewang chimericantigenreceptorcartcellimmunotherapyagainstthoracicmalignancieschallengesandopportunities AT ronghuang chimericantigenreceptorcartcellimmunotherapyagainstthoracicmalignancieschallengesandopportunities AT keli chimericantigenreceptorcartcellimmunotherapyagainstthoracicmalignancieschallengesandopportunities AT yujielei chimericantigenreceptorcartcellimmunotherapyagainstthoracicmalignancieschallengesandopportunities AT yunchaohuang chimericantigenreceptorcartcellimmunotherapyagainstthoracicmalignancieschallengesandopportunities |